Can Real-World data improve care for severe nasal polyps?
NCT ID NCT07795658
First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time
Summary
This study follows about 1,000 adolescents and adults in China with severe chronic rhinosinusitis with nasal polyps, a condition causing nasal blockage, loss of smell, and poor quality of life. Over 36 months, researchers will track the treatments patients actually receive, such as nasal sprays, surgery, or biologic drugs, and measure changes in symptoms and quality of life. The goal is to understand which treatment patterns lead to better long-term outcomes and to identify factors linked to persistent disease or the need for more intensive care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Routine clinical care for CRSwNP, including intranasal corticosteroids, systemic corticosteroids, endoscopic sinus surgery, biologic therapies, and other standard treatments
- What this could lead to
- If successful, this study could reveal which real-world treatments work best for severe nasal polyps in Chinese patients, guiding more effective and personalized care.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care and follow-up.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will comprise adolescents and adults aged 12 years or older with bilateral chronic rhinosinusitis with nasal polyps (CRSwNP) receiving routine clinical care at participating otolaryngology centers in China. Eligible participants will be enrolled prospectively and followed for 36 months. All treatment decisions, including medical therapy, endoscopic sinus surgery, and biologic therapy, will be made by treating physicians according to routine clinical practice and will not be assigned by the study.
- Ages
-
12 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 12 years or older at the time of signing the informed consent or assent form. * Confirmed diagnosis of chronic rhinosinusitis with bilateral nasal polyps (CRSwNP) according to the Chinese Guideline for Diagnosis and Treatment of Chronic Rhinosinusitis (2024). * Baseline Nasal Polyp Score (NPS) of at least 4 on a scale of 0 to 8, with a score of at least 1 in each nasal cavity. * At baseline, a self-reported Nasal Congestion Score (NCS) of at least 2 and/or Loss of Smell Score (LoS) of at least 2, each assessed on a scale of 0 to 3 based on symptoms during the previous 2 weeks. * Able and willing to comply with long-term clinical follow-up and study assessments. * Voluntary written informed consent. For minors, written informed consent from a parent or legal guardian and participant assent will be obtained as required by applicable regulations and ethics committee requirements. Exclusion Criteria: * Presence of another poorly controlled serious disease, recurrent chronic disease, or infectious disease. * Pregnancy or breastfeeding. * History of excessive alcohol consumption, defined as more than 14 units of alcohol per week (1 unit equals 360 mL of beer, 45 mL of spirits containing 40% alcohol, or 150 mL of wine), or a history of drug abuse. * Other concomitant conditions that may interfere with the study, including but not limited to fungal sinusitis except allergic fungal rhinosinusitis, odontogenic sinusitis, antrochoanal polyps, eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss syndrome), cystic fibrosis, granulomatosis with polyangiitis, Young syndrome, Kartagener syndrome, or other ciliary dyskinesia syndromes. * Any medical, social, psychological, or personal condition that, in the investigator's judgment, may interfere with participation or reasonably be expected to prevent completion of scheduled follow-up visits and assessments, such as limited life expectancy, substance abuse, or severe cognitive impairment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis with nasal polyps (CRSWNP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antibiotic keep nasal polyps from coming back?
- Can a new injection shrink nasal polyps and restore easy breathing?
- Could a Pre-Surgery drug boost nasal polyp treatment?
- New study tests tezepelumab for chronic sinusitis sufferers
- 88% of patients with asthma and nasal polyps achieve dual remission on dupilumab
- Scientists probe the root cause of smell loss in chronic sinusitis